Risk of lung cancer in Parkinson's disease

Xie, Xin; Luo, Xiaoguang; Xie, Mingliang; Liu, Yang; Wu, Ting

doi:10.18632/oncotarget.12964

Cited by 11 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Therefore, we evaluated tobacco smoking and the 2 cancers with very high (>80%) attributable risk for smoking (lung cancer and laryngeal cancer). [11][12][13] We made a dichotomous ever vs never smoking variable with 4 codes specific to tobacco use: history of smoking (ICD-9-CM V15.82), nicotine dependence (ICD-9-CM 305.1), and 2 procedure codes for tobacco cessation counseling (99406 and 99407). We also made a more comprehensive ever smoking variable.…”

Section: Ascertainment Of Other Medical Conditionsmentioning

confidence: 99%

Use of medical care biases associations between Parkinson disease and other medical conditions

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Ascertainment Of Other Medical Conditionsmentioning

confidence: 99%

Use of medical care biases associations between Parkinson disease and other medical conditions

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Interestingly, a large number of epidemiological studies have shown a significant reduction in the risk of cancer in patients with Parkinson’s disease (PD) [ 4 ]. A meta-analysis of 15 studies, involving 348,780 patients with PD, showed a significant negative correlation between PD and lung cancer risk (RR: 0.53, 95%CI: 0.41–0.70, P < 0.001) [ 5 ]. Both PD and lung cancer are multifactorial disorders involving genes and the environment.…”

Section: Introductionmentioning

confidence: 99%

SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma

Zhang

2022

BMC Cancer

View full text Add to dashboard Cite

Background The SNCA gene is a critical gene in Parkinson’s disease (PD) pathology. Accumulating evidence indicates that SNCA is involved in tumorigenesis; however, the role of SNCA in lung adenocarcinoma (LUAD) remains unclear. This study aimed to explore the potential value of SNCA as a prognostic and diagnostic molecular marker in LUAD. Methods In this study, we explored the expression pattern, prognostic value, and promoter methylation status of SNCA in LUAD based on Oncomine, UALCAN, and Kaplan–Meier Plotter. Then, using TIMER, we investigated the correlation between SNCA expression and immune infiltration. And cBioPortal were used to analysis the correlation between SNCA expression and immune checkpoint. The transcriptome data of A549 cells overexpressing SNCA were used to further study the potential immune role of SNCA in LUAD. The effect of SNCA on proliferation of A549 cells were evaluated by CCK-8, EdU and colony formation. Finally, LUAD cell lines treated with 5-aza-dC were used to explore the correlation between increased promoter methylation and downregulated mRNA expression of SNCA. Results In general, the expression level of SNCA in LUAD tissue was lower than that in normal tissue, and high expression of SNCA was related to better prognosis. There were significant positive correlations between SNCA expression and immune infiltrations, including CD8+ T cells, macrophages, neutrophils, dendritic cells, B cells, and CD4+ T cells, and immune checkpoints, suggesting that immune infiltration was one of the reasons for the influence of SNCA on prognosis in LUAD. The transcriptome data of A549 cells overexpressing SNCA were further used to screen the relevant immune-related genes regulated by SNCA. Enrichment analysis confirmed that SNCA participates in the PI3K-AKT signaling pathway and other key tumor signaling pathways and regulates the expression of MAPK3, SRC, PLCG1, and SHC1. Cellular proliferation assay showed that SNCA could inhabit the growth of A549 cells via inhibiting activity of PI3K/AKT/ mTOR pathway. Finally, analysis of the methylation level of SNCA promoter showed that the promoter methylation negatively correlated with mRNA level. The expression of SNCA in LUAD cell lines was significantly upregulated by treatment with 5-aza-dC. Conclusion High methylation of SNCA promoter in LUAD is one of the reasons for the downregulation of SNCA mRNA level. Given that SNCA could inhibit the proliferation of A549 cells and correlates with immune infiltrates, it may serve as a prognostic biomarker in LUAD.

show abstract

“…Nonetheless, DAs doses used for this condition are typically higher—as much as six times higher—when compared to those used in RLS 42 . As aforementioned, patients with PD were excluded from our main analysis because PD itself has been associated with a lower risk of developing different types of cancer 27–29 . However, we evaluated the effect of including patients diagnosed with PD after cohort entry as a sensitivity analysis; after inclusion of these patients, results did not vary, suggesting that our results are robust across study populations.…”

Section: Discussionmentioning

confidence: 99%

Dopamine agonists and risk of lung cancer in patients with restless legs syndrome

Hernandez‐Con

Shults

Willis

et al. 2023

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose To examine the association between long‐term use of dopamine agonists (DAs) and the risk of lung cancer in patients with restless legs syndrome (RLS). Methods We conducted a retrospective cohort study using Optum Clinformatics® database. We included adults ≥40 years diagnosed with RLS during the study period (1/2006–12/2016). Follow‐up started with the first RLS diagnosis and ended on the earliest of: incident diagnosis of lung cancer, end of enrollment in the database or end of the study period. The exposure of interest was cumulative duration of DAs use, measured in a time‐varying manner. We constructed a multivariable Cox regression model to estimate HRs and 95% CIs for the association between lung cancer and cumulative durations of DA use, adjusting for potential confounding variables. Results We identified 295 042 patients with a diagnosis of RLS. The mean age of the cohort was 62.9; 66.6% were women and 82.3% were white. The prevalence of any DA exposure was 40.3%. Compared to the reference group (no use and ≤1 year), the crude HRs for lung cancer were 1.16 (95% CI 0.99–1.36) and 1.14 (95% CI 0.86–1.51) for 1–3 years and >3 years of cumulative DA use, respectively. The adjusted HR for lung cancer was 1.05 (95% CI 0.88–1.25) for 1–3 years and 1.02 (95% CI 0.76–1.37) for >3 years of cumulative DA use, respectively. Conclusions At typical doses for the clinical management of RLS, long‐term DA use was not associated with risk of lung cancer.

show abstract

Risk of lung cancer in Parkinson's disease

Cited by 11 publications

References 38 publications

Use of medical care biases associations between Parkinson disease and other medical conditions

Use of medical care biases associations between Parkinson disease and other medical conditions

SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma

Dopamine agonists and risk of lung cancer in patients with restless legs syndrome

Contact Info

Product

Resources

About